How Should Performance Verification Materials Be Prepared for Medical Device Registration in the Philippines?

To prepare performance verification materials for medical device registration in the Philippines, a manufacturer should first confirm the target country, the product risk classification, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete files or unresolved authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the most reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Published: 2026-07-11 08:58   Updated: 2026-07-11 08:58

This article addresses the questions companies most often need to resolve first in real international registration projects, covering international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Regulatory Assessment Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-up Questions
• Further Reading
• Scope of Application

Key Summary

On the question of how to prepare performance verification materials for medical device registration in the Philippines, a manufacturer should first confirm the target country, the product risk classification, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete documentation or unresolved authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the most reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market typically affects the technical file, authorized representative arrangements, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents must be submitted, it is likely to encounter deficiency notices or rework in areas such as model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends that companies plan this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for guidance on preparing performance verification materials for Philippine registration are usually not looking for a conceptual explanation. They want to judge whether existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines are being extended, and which issues could affect the launch plan. Behind this question there are usually several connected matters: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first prepare reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then localize them according to each country's regulatory requirements.

Regulatory Assessment Logic

A manufacturer should first confirm the intended use, mechanism of action, use environment, method and duration of body contact, sterility, whether the device is powered, and whether it contains software or has IVD characteristics. Only then should the risk classification and submission pathway be determined. Once the pathway assessment is wrong, all subsequent translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains the documentation for certificate renewal. If these issues are handled vaguely only in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. A regulatory authority focuses on whether the device is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the target market pathway.
• Too many models and specifications, with insufficient coverage in test reports, clinical evidence or labelling.
• Selecting a local agent solely on commercial sales considerations, without clarifying regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and claims in the registration file, leading to deficiency notices or post-market compliance risk.
• Failure to plan for multi-country document reuse in advance, resulting in repeated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to confirm the documentation base using an internal checklist, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a country-specific gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI Perspective

AIMEILI recommends that companies not treat target market registration as a one-off document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to each country's requirements is usually faster, more stable and more conducive to subsequent changes and certificate renewal than compiling documentation country by country on an ad hoc basis.

From a project management perspective, three things should be controlled as early as possible: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, a project may still face repeated rounds of deficiency responses, agent communication and post-market maintenance work, even when the documentation appears substantial.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for registration in the target market?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the document structure, language, labelling, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after confirming the target market and the product list. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent is usually involved in registration communication, changes, certificate renewal and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project ledger that manages the product list, model and specification matrix, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and enables management to judge whether the project will affect the launch plan.

Companies that already have registration bases in several countries should also establish an evidence reuse matrix, specifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept at consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities generally examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the product being submitted, or if the manufacturing address, model and specification, or instructions for use version is inconsistent with the test report, a company may be asked for supplementary explanations even after preparing a large number of documents.

Before submission, companies should establish an evidence consistency checklist that maps the product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiency notices, particularly for projects submitted simultaneously in several GHWP member states or involving multiple product families.

Localization Conversion and Agent Responsibilities

Target market registration projects usually involve arrangements with a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort at the certification stage but neglect post-market maintenance, so that a manufacturing address change, model extension, instructions for use update or agent replacement can later leave the certificate out of step with actual market sales.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and certificate renewal milestones. The value of this approach is not only greater efficiency in registering in a single country, but more importantly enabling companies to build a repeatable overseas compliance capability and reduce the cost of organizing documentation from zero each time they enter a new market.

Further Reading

• Previous: What Are the Requirements for Risk Management Documentation in Philippine Medical Device Registration?
• Next: What Should Be Done When Quality System Evidence Is Inconsistent in Philippine Medical Device Registration?

Recommended Reading

• What Are the Requirements for Risk Management Documentation in Philippine Medical Device Registration?
• What Should Be Done When Quality System Evidence Is Inconsistent in Philippine Medical Device Registration?
• How Should Registration Documentation Be Prepared for Medical Device Registration in Singapore?
• How Should Product Classification Be Determined for Medical Device Registration in Singapore?
• How Should the Technical File Be Organized for Medical Device Registration in Singapore?
• How Should Labelling and Instructions for Use Be Localized for Medical Device Registration in Singapore?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.